250 related articles for article (PubMed ID: 30861422)
1. A tetrameric protein scaffold as a nano-carrier of antitumor peptides for cancer therapy.
Ma B; Niu F; Qu X; He W; Feng C; Wang S; Ouyang Z; Yan J; Wen Y; Xu D; Shao Y; Ma PX; Lu W
Biomaterials; 2019 Jun; 204():1-12. PubMed ID: 30861422
[TBL] [Abstract][Full Text] [Related]
2. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.
Niu F; Yan J; Ma B; Li S; Shao Y; He P; Zhang W; He W; Ma PX; Lu W
Biomaterials; 2018 Jun; 167():132-142. PubMed ID: 29571049
[TBL] [Abstract][Full Text] [Related]
3. Resurrecting a p53 peptide activator - An enabling nanoengineering strategy for peptide therapeutics.
He W; Yan J; Li Y; Yan S; Wang S; Hou P; Lu W
J Control Release; 2020 Sep; 325():293-303. PubMed ID: 32653500
[TBL] [Abstract][Full Text] [Related]
4. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
5. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
6. Design of stapled peptide-based PROTACs for MDM2/MDMX atypical degradation and tumor suppression.
Chen S; Li X; Li Y; Yuan X; Geng C; Gao S; Li J; Ma B; Wang Z; Lu W; Hu HG
Theranostics; 2022; 12(15):6665-6681. PubMed ID: 36185610
[No Abstract] [Full Text] [Related]
7. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
[TBL] [Abstract][Full Text] [Related]
8. Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression.
Li X; Gohain N; Chen S; Li Y; Zhao X; Li B; Tolbert WD; He W; Pazgier M; Hu H; Lu W
Acta Pharm Sin B; 2021 Sep; 11(9):2655-2669. PubMed ID: 34589387
[TBL] [Abstract][Full Text] [Related]
9. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
Hu B; Gilkes DM; Chen J
Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
[TBL] [Abstract][Full Text] [Related]
10. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
[TBL] [Abstract][Full Text] [Related]
11. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
12. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
13. d-Amino acid mutation of PMI as potent dual peptide inhibitors of p53-MDM2/MDMX interactions.
Li X; Liu C; Chen S; Hu H; Su J; Zou Y
Bioorg Med Chem Lett; 2017 Oct; 27(20):4678-4681. PubMed ID: 28916339
[TBL] [Abstract][Full Text] [Related]
14. A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity.
Yan S; Yan J; Liu D; Li X; Kang Q; You W; Zhang J; Wang L; Tian Z; Lu W; Liu W; He W
Theranostics; 2021; 11(14):6833-6846. PubMed ID: 34093856
[TBL] [Abstract][Full Text] [Related]
15. Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
Cornillie SP; Bruno BJ; Lim CS; Cheatham TE
J Phys Chem B; 2018 Apr; 122(14):3864-3875. PubMed ID: 29519125
[TBL] [Abstract][Full Text] [Related]
16. Self-Assembled Peptide-Lanthanide Nanoclusters for Safe Tumor Therapy: Overcoming and Utilizing Biological Barriers to Peptide Drug Delivery.
Yan J; He W; Yan S; Niu F; Liu T; Ma B; Shao Y; Yan Y; Yang G; Lu W; Du Y; Lei B; Ma PX
ACS Nano; 2018 Feb; 12(2):2017-2026. PubMed ID: 29376322
[TBL] [Abstract][Full Text] [Related]
17. A Hierarchical Peptide-Lanthanide Framework To Accurately Redress Intracellular Carcinogenic Protein-Protein Interaction.
Yan J; Yan S; Hou P; Lu W; Ma PX; He W; Lei B
Nano Lett; 2019 Nov; 19(11):7918-7926. PubMed ID: 31645103
[TBL] [Abstract][Full Text] [Related]
18. Awakening p53
Bian Z; Yan J; Wang S; Li Y; Guo Y; Ma B; Guo H; Lei Z; Yin C; Zhou Y; Liu M; Tao K; Hou P; He W
Theranostics; 2018; 8(19):5320-5335. PubMed ID: 30555549
[TBL] [Abstract][Full Text] [Related]
19. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
20. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]